Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab in Advanced Solid Tumors

NCT04074967 is registered in ClinicalTrials.gov with Dan Zandberg as lead sponsor.

NCT NCT04074967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04074967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab in Advanced Solid Tumors
Lead sponsor
Dan Zandberg
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 11, 2020
Completion date
December 31, 2025
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, melanoma, non-small cell lung cancer, renal cell carcinoma, solid tumor